Skip to main content

Table 2 Treatment-related adverse events: worst grade per patient in all cycles in at least 10% of all patients, n (%)

From: Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

Adverse event Gradea Total
1 2 3 4 5
Blood and lymphatic system disorders
 Hypertension 3 (16.7) 1 (5.6) 2 (11.1) 0 0 6 (33.3)
 Vaginal hemorrhage 2 (11.1) 0 0 0 0 2 (11.1)
Endocrine disorders
 Hypothyroidism 7 (38.9) 0 0 0 0 7 (38.9)
Metabolism and nutrition disorders
 Hypertriglyceridemia 5 (27.8) 1 (5.6) 0 0 0 6 (33.3)
 Decreased appetite 0 2 (11.1) 0 0 0 2 (11.1)
Respiratory, thoracic, and mediastinal disorders
 Dysphonia 2 (11.1) 0 0 0 0 2 (11.1)
Gastrointestinal disorders
 Nausea 4 (22.2) 0 0 0 0 4 (22.2)
 Abdominal pain 2 (11.1) 0 0 0 0 2 (11.1)
 Diarrhea 2 (11.1) 1 (5.6) 0 0 0 3 (16.7)
 Mouth ulceration 1 (5.6) 1 (5.6) 0 0 0 2 (11.1)
Renal and urinary disorders
 Proteinuria 8 (44.4) 0 0 0 0 8 (44.4)
 Hematuria 7 (38.9) 0 0 0 0 7 (38.9)
Skin and subcutaneous tissue disorders
 Rash 1 (5.6) 1 (5.6) 0 0 0 2 (11.1)
 Palmar-plantar erythrodysesthesia syndrome 1 (5.6) 1 (5.6) 0 0 0 2 (11.1)
General disorders and administration site conditions
 Fatigue 7 (38.9) 4 (22.2) 0 0 0 11 (61.1)
Lab examinations
 Leucopenia 2 (11.1) 1 (5.6) 0 0 0 3 (16.7)
 ALT increased 2 (11.1) 0 0 0 0 2 (11.1)
 Amylase increased 3 (16.7) 1 (5.6) 0 0 0 4 (22.2)
 Conjugated bilirubin increased 5 (27.8) 0 0 0 0 5 (27.8)
 Neutropenia 2 (11.1) 0 2 (11.1) 0 0 4 (22.2)
 AST increased 3 (16.7) 0 0 0 0 3 (16.7)
 Hyperbilirubinemia 2 (11.1) 0 0 0 0 2 (11.1)
 Unconjugated bilirubin increased 2 (11.1) 0 0 0 0 2 (11.1)
 Blood urea increased 2 (11.1) 0 0 0 0 2 (11.1)
 Thrombocytopenia 2 (11.1) 0 0 0 0 2 (11.1)
  1. Patients with multiple events in the same category are counted only once in that category; patients with events in more than one category are counted once in each of those categories
  2. ALT alanine amino-transferase, AST aspartate amino-transferase
  3. aGraded per National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0